Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M

Apogee Therapeutics, Inc.

2025-Q2 EPS reported -$2.08

APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).
Cash, cash equivalents and marketable securities at $621.2M as of June 30, 2025; runway into Q1 2028.
Net loss of $66.1M for Q2 2025, up from $33.8M in Q2 2024, driven by higher R&D expenses.
Phase 2 Part B readout accelerated to mid-2026; Phase 3 plans on track for 2026.
First patient dosed in Phase 1b combination trial of APG279 vs DUPIXENT in atopic dermatitis.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.